Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Immunocore has a “Moderate Buy” consensus rating from 12 analysts: six buys, one strong buy, four holds and one sell. The average 12-month price target is $56.38.
• Shares opened at $32.18, versus a 12-month range of $27.56 to $40.71, suggesting analyst targets imply potential upside. The company has a market capitalization of approximately $1.66 billion.
• Immunocore reported quarterly EPS of $(0.02), missing the $(0.01) consensus estimate, while institutional investors own approximately 84.5% of its outstanding shares.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $56.3750.

Several research analysts recently commented on the stock. Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a report on Tuesday, July 28th. Weiss Ratings reissued a "sell (e+)" rating on shares of Immunocore in a research report on Friday, July 17th. Zacks Research downgraded shares of Immunocore from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 3rd. Mizuho lifted their target price on shares of Immunocore from $34.00 to $35.00 and gave the company a "neutral" rating in a report on Monday, August 3rd. Finally, JPMorgan Chase & Co. started coverage on shares of Immunocore in a research report on Friday, August 21st. They set an "overweight" rating and a $50.00 price target for the company.

Immunocore Price Performance

Shares of Immunocore stock opened at $32.18 on Tuesday. Immunocore has a twelve month low of $27.56 and a twelve month high of $40.71. The stock has a market capitalization of $1.66 billion, a P/E ratio of -86.97 and a beta of 0.74. The company has a current ratio of 4.47, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. The business's fifty day moving average price is $34.67 and its 200 day moving average price is $31.79.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. As a group, research analysts anticipate that Immunocore will post 0.06 earnings per share for the current year.

Institutional Investors Weigh In On Immunocore

Several institutional investors and hedge funds have recently modified their holdings of IMCR. Harbour Investments Inc. boosted its holdings in Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company's stock worth $36,000 after acquiring an additional 388 shares during the period. Leonteq Securities AG purchased a new stake in shares of Immunocore during the fourth quarter valued at approximately $30,000. Hennion & Walsh Asset Management Inc. raised its stake in shares of Immunocore by 2.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,324 shares of the company's stock valued at $1,534,000 after purchasing an additional 1,197 shares during the period. GAMMA Investing LLC lifted its position in shares of Immunocore by 202.8% during the second quarter. GAMMA Investing LLC now owns 1,920 shares of the company's stock worth $61,000 after purchasing an additional 1,286 shares in the last quarter. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Immunocore during the fourth quarter worth $47,000. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc is a biotechnology company that develops T-cell receptor (TCR) therapies designed to direct the immune system against cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-related peptides presented on the surface of cells and recruit T cells to destroy targeted cells.

The company's lead product is KIMMTRAK (tebentafusp-tebn), an ImmTAC therapy approved in the United States, European Union and other markets for the treatment of unresectable or metastatic uveal melanoma in certain patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.